Harmony Biosciences Holdings, Inc. (HRMY)
Automate Your Wheel Strategy on HRMY
With Tiblio's Option Bot, you can configure your own wheel strategy including HRMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HRMY
- Rev/Share 14.127
- Book/Share 14.284
- PB 2.6239
- Debt/Equity 0.2032
- CurrentRatio 3.7546
- ROIC 0.1808
- MktCap 2158711498.0
- FreeCF/Share 5.0781
- PFCF 7.271
- PE 11.8017
- Debt/Assets 0.1405
- DivYield 0
- ROE 0.2486
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HRMY | Truist | -- | Buy | -- | $48 | July 21, 2025 |
| Resumed | HRMY | Goldman | -- | Neutral | -- | $33 | July 10, 2025 |
| Resumed | HRMY | Oppenheimer | -- | Outperform | -- | $61 | June 2, 2025 |
| Initiation | HRMY | Deutsche Bank | -- | Buy | -- | $55 | Feb. 11, 2025 |
| Initiation | HRMY | H.C. Wainwright | -- | Buy | -- | $75 | Dec. 17, 2024 |
| Resumed | HRMY | Raymond James | -- | Outperform | -- | -- | Oct. 10, 2024 |
| Initiation | HRMY | UBS | -- | Buy | -- | $56 | Sept. 10, 2024 |
News
5 Value Picks Amid AI-Driven Tech Sell-Off & U.S.-Iran Tensions
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Negative
AI fears and U.S.-Iran tensions rattle markets. Value investors should consider buying stocks like HRMY, AGRO, SQM, ANGI and PHIN.
Read More
4 Value Stocks to Consider as Tech Volatility Weighs on Wall Street
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Tech turmoil weighs on Wall Street, but CNXC, GPN, HRMY, and UHS stand out with low P/CF ratios and solid growth.
Read More
Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
Read More
HRMY or ARGX: Which Is the Better Value Stock Right Now?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Buy These 5 Price-to-Book Value Stocks for Gains in 2026
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Five low price-to-book stocks stand out for 2026, as undervalued valuations and solid growth outlooks put them on investors' radar.
Read More
Harmony Biosciences (HRMY) is an Incredible Growth Stock: 3 Reasons Why
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
HRMY vs. LQDA: Which Stock Is the Better Value Option?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Liquidia Corporation (LQDA). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Harmony Biosciences to Participate in Upcoming Investor Conferences
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Citi's 2025 Global Healthcare Conference Location: Miami, FL Tuesday, December 2, 2025 8th Annual Evercore Healthcare Conference Location: Miami, FL Fireside Chat: Tuesday, December 2, 2025, at 2:35 p.m. ET Piper Sandler 37th Annual Healthcare Conference Location: New York, NY Fireside Chat: Wed.
Read More
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call Transcript
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Harmony Biosciences Holdings, Inc. ( HRMY ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Matthew Beck Jeffrey Dayno - President, CEO & Director Adam Zaeske - Executive VP & Chief Commercial Officer Kumar Budur - Executive VP and Chief Medical & Scientific Officer Sandip Kapadia - Executive VP, Chief Administrative Officer & CFO Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Pete Stavropoulos - …
Read More
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.79 per share a year ago.
Read More
3 Biotech Stocks I Am Accumulating
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Positive
The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call trade candidates due to the liquidity and lucrativeness of the option premiums against these equities. Stocks had their biggest decline last Friday since the first half of April due to escalating trade tensions between the U.S. and China.
Read More
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Read More
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.2 per share a year ago.
Read More
5 High Earnings Yield Stocks to Tap Into Value Investing Gains
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Unlock value with IAG, PAGP, HOPE, COMM and HRMY, five stocks with high earnings yields and strong growth signals.
Read More
Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
Read More
HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
Read More
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin's Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will be dismissed, and Lupin will receive a license to launch its generic product n.
Read More
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Company Participants Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executive Officer Adam Zaeske - Chief Commercial Officer Kumar Budur - Chief Medical and Scientific Officer Sandip Kapadia - Chief Financial Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities David Amsellem - Piper Sandler Ami Fadia - Needham Patrick Trucchio - H.C. Wainwright David Hoang - Deutsche Bank Ash Verma - UBS Jason Gerberry - Bank of America Charles Duncan - Cantor Fitzgerald Operator Good morning.
Read More
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.67 per share a year ago.
Read More
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its way to a potential $1B+ opportunity in narcolepsy alone and poised for additional growth from its next-gen pitolisant development programs. The company has demonstrated four consecutive years of profitability and has grown its cash and investments position to over $600M. “Building off of our strong fou.
Read More
Why Harmony Biosciences (HRMY) Could Beat Earnings Estimates Again
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Read More
About Harmony Biosciences Holdings, Inc. (HRMY)
- IPO Date 2020-08-19
- Website https://www.harmonybiosciences.com
- Industry Biotechnology
- CEO Jeffrey Dayno
- Employees 268